Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

diabetic nephropathies/obesity

リンクがクリップボードに保存されます
ページ 1 から 35 結果
FIELD OF THE INVENTION The present invention relates generally to methods and compositions for use in the prevention or treatment of risk factors for cardiovascular diseases such as obesity, metabolic syndrome, diabetes, and vascular and renal disorders. More particularly, the present invention

Morphinan-derivatives for treating diabetes and related disorders

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF INVENTION The invention relates to morphinan-derivatives, pharmaceutical compositions containing such morphinan-derivatives and the use of those morphinan-derivatives and/or compositions for treating diseases and conditions in man and other mammals, either alone or in combination with other

Synthesis of 3,3,4,4-tetrafluoropyrrolidine and novel dipeptidyl peptidase-IV inhibitor compounds

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF INVENTION The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV`) inhibitor compounds and a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds. BACKGROUND OF

Benzene compounds

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to benzene compounds, and more particularly, to novel benzene compounds having inhibition activity on acetyl CoA carboxylase ("ACC" hereinafter). 2. Discussion of the Background It has become clear in recent years

Methods and compositions for the inhibition of fructokinase

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF THE INVENTION The present inventors have identified fructokinase as a key enzyme that drives a host of metabolic conditions characterized by sugar craving, obesity, metabolic syndrome, and renal disease. In particular, isoform specific inhibitors targeting fructokinase C, or both

Lactam compound, a method for producing the same, and a diabetic therapy by administering the same

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a medicinal drug, and in particular, to a novel lactam compound having sugar transport enhancement action and having excellent hypoglycemic action, a preparation method thereof, and a preparation intermediate

Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled A-1824-US-PCT_SeqList.txt, created Jun. 5, 2015 which is 33 KB size. The information in the electronic format of the Sequence Listing is incorporated herein

Secreted frizzle-related protein 5 (SFRP5) binding proteins

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled A-1830-US-PCT_SeqList.txt, created Jun. 5, 2015, which is 45 KB in size. The information in the electronic format of the Sequence Listing is incorporated

Growth differentiation factor 15 (GDF-15) constructs

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 29, 2014, is named A-1850-WO-PCT_SL.txt and is 630,200 bytes in size. FIELD OF THE

Growth differentiation factor 15 (GDF-15) polypeptides

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
SEQUENCE LISTING The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled A-1682-US-CNT_SeqList.txt, created Jun. 14, 2017, which is 247 KB in size. The information in the electronic format of the Sequence Listing
FIELD OF THE INVENTION The present disclosure relates to the treatment or amelioration of a metabolic disorder, such as type 2 diabetes, elevated glucose levels, elevated insulin levels, obesity, non-alcoholic fatty liver disease, or cardiovascular diseases, using an antigen binding protein specific

Growth differentiation factor 15 (GDF-15) polypeptides

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 28, 2013, is named A1682WOP.txt and is 253,155 bytes in size. FIELD OF THE INVENTION The

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
1. FIELD OF THE INVENTION The invention relates to cycloalkyl-hydroxyl compounds and pharmaceutically acceptable salts, hydrates, solvates, and mixtures thereof; compositions comprising a hydroxyl compound or a pharmaceutically acceptable salt, hydrate, solvate, or mixtures thereof; and methods for

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
1. FIELD OF THE INVENTION The invention relates to cycloalkyl-hydroxyl compounds and pharmaceutically acceptable salts, hydrates, solvates, and mixtures thereof; compositions comprising a hydroxyl compound or a pharmaceutically acceptable salt, hydrate, solvate, or mixtures thereof; and methods for

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
1. FIELD OF THE INVENTION The invention relates to cycloalkyl-hydroxyl compounds and pharmaceutically acceptable salts, hydrates, solvates, and mixtures thereof; compositions comprising a hydroxyl compound or a pharmaceutically acceptable salt, hydrate, solvate, or mixtures thereof; and methods for
Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge